Document is current
Any future updates will be listed below
-
Authors
Lee, Won Suk https://orcid.org/0000-0003-2753-5294
Lee, Seung Joon
Lee, Hye Jin
Yang, Hannah https://orcid.org/0000-0003-2252-7041
Go, Eun-Jin
Gansukh, Enkhtaivan
Song, Ki-Hoon
Xiang, Xiao
Park, Dong Guk https://orcid.org/0000-0002-9894-9104
Alain, Tommy
Chon, Hong Jae https://orcid.org/0000-0002-6979-5812
Kim, Chan https://orcid.org/0000-0001-9780-6155
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (NRF-2023R1A2C2006375, NRF-2023R1A2C2004339)
Canadian Cancer Society Research Institute (CHA-#707351)
Cancer Research Society (CRS-839202)
- License Information
-
More Information
Article History
Received: 19 September 2023
Accepted: 2 October 2024
First Online: 22 October 2024
Competing interests
: C.K. has a consulting or advisory role at Roche, MSD, BMS, ONO, Oncocross, Virocure, and Sillajen, and has received research grants from Panolos Bioscience, Boryung Pharmaceuticals, Oncocross, Sillajen, and Virocure. H.J.C. has a consulting or advisory role at Roche, Bayer, ONO, MSD, BMS, Celgene, Sanofi, Servier, AstraZeneca, Eisai, Sillajen, Menarini, GreenCross Cell, and Virocure and has received research grants from Panolos Bioscience, Roche and Boryung Pharmaceuticals. E.G., K-H.S. and D.G.P. are employees of Virocure. T.A. has a consulting and advisory role at Virocure, CuroV Science and Genvira Biosciences. The other authors declare no competing interests.
